Description
Murine mAb m5/44 was humanized by CDR grafting to create g5/44. The clone g5/44 bind CD22 with subnanomolar affinity. Based on shown results, a calicheamicin conjugate of g5/44, CMC-544, was selected for further development as a targeted chemotherapeutic agent for the treatment of B-cell malignancies.
Target
CD22
Target Alias Names
SIGLEC2, SIGLEC-2
Isotype/Mimetic
Humanized IgG4
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression